A strong week for clinical-stage MedTech, with investors doubling down on technologies built for clinical impact – this week’s tracker highlights major raises across AI imaging, cardiovascular devices, and robotic surgery. Details follow below.
CereVasc closes $85M Series C to support eShunt system
Piper Sandler Merchant Banking led the financing round for the Boston-based company. Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson’s corporate venture capital arm, and Medtronic also participated, as did existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.
The company plans to use funds to support its ongoing STRIDE pivotal trial in patients with normal pressure hydrocephalus.
CEO Dan Levangie
Last week’s tracker: RaysightMed, Zentek & more
Subtle Medical raises $33M to advance AI image software
The Series C financing round was led by Morgan Stanley Expansion Capital. With additional participation from Shinhan Venture Investment and existing investors, including Fusion Fund, BRV, and Samsung Ventures, the latest proceeds bring Subtle’s total funds raised to date to $86M.
With the funds in hand, Subtle intends to focus on advancing the development and market penetration of its lead products globally.
CEO Ohad Arazi
Advanced NanoTherapies raises $31M for drug-coated balloon tech
An undisclosed strategic investor, along with S3 Ventures, co-led the oversubscribed Series B round. The T45 Fund and new and existing investors also participated. Funding adds to $4M raised in 2023.
The funds support the company’s therapies for coronary and peripheral artery disease (CAD/PAD).
CEO Marwan Berrada-Sounni
Veritas Aortic Solutions raises $12M for aortic disease treatment advance
The seed financing round was led by a group of angel investors, with additional participation from Cedars-Sinai Intellectual Property Company, along with existing investors of inQB8 Medical Technologies, which Veritas spun out from in late 2025.
The proceeds will support the continued development of Veritas’ transcatheter valved aortic root conduit (TVARC) technology through first-in-human clinical use, the company stated.
CEO Brent Ratz
Petal Surgical adds more funding for incisionless surgical robot
Blue Pool Capital led the latest financing round for the company, which emerged from stealth with a $10M Series A last fall. Salience Capital, A&E Investments, TIME Ventures and existing investors, including Actions Capital (formerly K50 Ventures) participated, too.
The company said its Series A brought its total funding to $20 million at the time. Then, in March, it said that total eclipsed $25 million through another financing round.
Founder Prash Chopra
